HCA vs OMCL: fair value comparison
HCA Healthcare, Inc. and Omnicell, Inc. · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HCA currently sits closer to the top of our discount ranking. HCA carries the stronger quality grade.
| HCA | OMCL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $405.00 | $37.65 |
| 12-month range | $370.96–$532.92 | $29.96–$48.70 |
| Sector rank | #52 of 113 Healthcare | #54 of 113 Healthcare |
| Quality grade | C | D |
| Leverage | Low | Low |
| Margin trend | Stable | — |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Fairly Valued | — |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: HCA fair value analysis · OMCL fair value analysis